| Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia A Joutel, C Corpechot, A Ducros, K Vahedi, H Chabriat, P Mouton, ... Nature 383 (6602), 707-710, 1996 | 2482 | 1996 |
| EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis GM Hirschfield, U Beuers, C Corpechot, P Invernizzi, D Jones, M Marzioni, ... Journal of hepatology 67 (1), 145-172, 2017 | 978 | 2017 |
| Strong clustering and stereotyped nature of Notch3 mutations in CADASIL patients A Joutel, K Vahedi, C Corpechot, A Troesch, H Chabriat, C Vayssière, ... The Lancet 350 (9090), 1511-1515, 1997 | 796 | 1997 |
| Biochemical response to ursodeoxycholic acid and long‐term prognosis in primary biliary cirrhosis C Corpechot, L Abenavoli, N Rabahi, Y Chrétien, T Andréani, C Johanet, ... Hepatology 48 (3), 871-877, 2008 | 756 | 2008 |
| Hypoxia‐induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis C Corpechot, V Barbu, D Wendum, N Kinnman, C Rey, R Poupon, ... Hepatology 35 (5), 1010-1021, 2002 | 601 | 2002 |
| Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC C Corpechot, A El Naggar, A Poujol‐Robert, M Ziol, D Wendum, ... Hepatology 43 (5), 1118-1124, 2006 | 567 | 2006 |
| Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study WJ Lammers, HR van Buuren, GM Hirschfield, HLA Janssen, P Invernizzi, ... Gastroenterology 147 (6), 1338-1349. e5, 2014 | 516 | 2014 |
| A placebo-controlled trial of bezafibrate in primary biliary cholangitis C Corpechot, O Chazouillères, A Rousseau, A Le Gruyer, F Habersetzer, ... New England Journal of Medicine 378 (23), 2171-2181, 2018 | 486 | 2018 |
| Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome C Corpechot, O Chazouillères, R Poupon Journal of hepatology 55 (6), 1361-1367, 2011 | 484 | 2011 |
| The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis C Corpechot, F Carrat, A Bahr, Y Chrétien, RE Poupon, R Poupon Gastroenterology 128 (2), 297-303, 2005 | 481 | 2005 |
| Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy WJ Lammers, GM Hirschfield, C Corpechot, F Nevens, KD Lindor, ... Gastroenterology 149 (7), 1804-1812. e4, 2015 | 444 | 2015 |
| The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis C Corpechot, F Carrat, AM Bonnand, RE Poupon, R Poupon Hepatology 32 (6), 1196-1199, 2000 | 396 | 2000 |
| Noninvasive elastography‐based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis C Corpechot, F Carrat, A Poujol‐Robert, F Gaouar, D Wendum, ... Hepatology 56 (1), 198-208, 2012 | 382 | 2012 |
| Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial M Rosenzwajg, R Lorenzon, P Cacoub, HP Pham, F Pitoiset, K El Soufi, ... Annals of the rheumatic diseases 78 (2), 209-217, 2019 | 332 | 2019 |
| Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing … C Corpechot, F Gaouar, A El Naggar, A Kemgang, D Wendum, R Poupon, ... Gastroenterology 146 (4), 970-979. e6, 2014 | 310 | 2014 |
| Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis C Corpechot, Y Chrétien, O Chazouillères, R Poupon Journal of hepatology 53 (1), 162-169, 2010 | 295 | 2010 |
| Hepatocellular hypoxia-induced vascular endothelial growth factor expression and angiogenesis in experimental biliary cirrhosis O Rosmorduc, D Wendum, C Corpechot, B Galy, N Sebbagh, J Raleigh, ... The American journal of pathology 155 (4), 1065-1073, 1999 | 242 | 1999 |
| Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients C Corpechot, F Carrat, R Poupon, RE Poupon Gastroenterology 122 (3), 652-658, 2002 | 217 | 2002 |
| Bile salts control the antimicrobial peptide cathelicidin through nuclear receptors in the human biliary epithelium E d'Aldebert, MJBB Mve, M Mergey, D Wendum, D Firrincieli, A Coilly, ... Gastroenterology 136 (4), 1435-1443, 2009 | 215 | 2009 |
| Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis MH Harms, HR van Buuren, C Corpechot, D Thorburn, HLA Janssen, ... Journal of Hepatology 71 (2), 357-365, 2019 | 208 | 2019 |
Fabrice CarratProfessor Public health, epidemiology, biostatistics, university paris 6Verified email at u707.jussieu.fr
